Clinical Investigation On Drug Interaction of CVD: Evaluation on LCMS

One of the Pharmaceutical tablet dosage form which categorized under Cardiovascular combined formulation (Atorvastatin 10mg & Olmesartan 20mg) discloses Clinical, Markets, patients and community health feedbacks and reported high morbidity rate on chronic stage therapy. Though logics behind Atorvastatin (ATVS) & Olmesartan (OLM) combination i.e, Anti-atherosclerotic & anti-hypertensive must flourish best anti-hypertensive activity, but in real fact it¿s just reverse. The false propitious prescription persisting this formulation is unsafe for health and thus required post marketed re-investigation as per concerning Pharmacovigilance study. The misuse and malpractice of drugs by clinicians in patient¿s population particularly targeted hypertensive volunteers, on relying to this anti-hypertensive /Cardiovascular drug formulation seems to be hazardous to individual as well as community health. So, evaluation of this fact was undertaken in PhD project with scrutinizing all physiological parameters correlating to endogenous biochemical systemic variation depending on these drugs pharmacology.